Table 6 The trend in change of antimicrobial susceptibility to Alcaligenes faecalis analyzed by linear-by-linear association in chi-square test
From: Extensively drug-resistant Alcaligenes faecalis infection
Antibiotics/year (number of patients) | 2014 (12) | 2015 (13) | 2016 (9) | 2017 (9) | 2018 (7) | 2019 (9) | M2 | P value |
|---|---|---|---|---|---|---|---|---|
CAZ | 100% | 92.3% | 77.8% | 88.7% | 85.7% | 66.7% | 4.063 | 0.044 |
GEN | 100% | 84.6% | 55.6% | 77.8% | 71.4% | 55.6% | 5.144 | 0.023 |
AMK | 100% | 84.6% | 100% | 100% | 85.7% | 55.6% | 5.837 | 0.016 |
CIP | 50.0% | 61.5% | 22.2% | 22.2% | 42.9% | 33.3% | 1.589 | 0.207 |
IMP | 100% | 100% | 100% | 100% | 85.7% | 66.7% | 9.042 | 0.003 |
SAM | 100% | 84.6% | 77.8% | 88.7% | 85.7% | 55.6% | 4.622 | 0.032 |
FEP | 83.3% | 76.9% | 77.8% | 66.7% | 71.4% | 55.6% | 2.028 | 0.154 |
MEM | 100% | 100% | 100% | 100% | 85.7% | 66.7% | 9.042 | 0.003 |
TZP | 100% | 84.6% | 33.3% | 42.4% | 57.1% | 33.3% | 11.713 | 0.001 |